Intravenous gamma globulin in the management of patients with hypogammaglobulinemia

Daniel B. Magilavy*, James T. Cassidy, David G. Tubergen, Ross E. Petty, Rex Chisholm, Keith McCall

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The safety and efficacy of plasmin-treated gamma globulin (PT-GG), an intravenous preparation with low anticomplementary activity, was assessed as an antibody replacement therapy in 14 patients with hypogammaglobulinemia. Seven patients were studied in 2 treatment periods of 6 and 15 mo on PT-GG with an intervening control period of intramuscular gamma globulin (IM-ISG). Frequency of infusions ranged from 2 to 4 wk to maintain a serum IgG concentration of <2.5 mg /ml. Three patients with severe chronic pulmonary disease were removed from the study because of lack of clinical improvement and were placed on single-donor plasma. The remaining 11 patients had a decrease in the number of hospitalizations or severe infections. Five patients had one or more systemic reactions (21/240 infusions). Symptoms abated rapidly with temporary interruption of the infusion. From these results, we conclude that PT-GG represents a relatively safe, efficacious mode of replacement therapy which has had uniformly high acceptance in patients with hypogammaglobulinemia.

Original languageEnglish (US)
Pages (from-to)378-383
Number of pages6
JournalThe Journal of allergy and clinical immunology
Issue number6
StatePublished - Jun 1978

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Intravenous gamma globulin in the management of patients with hypogammaglobulinemia'. Together they form a unique fingerprint.

Cite this